SCHEMBL22490773

SCHEMBL22490773

O=C(O)c1csc(NS(=O)(=O)C2CC2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTPS1 P17812 14/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
CTPS2 Q9NRF8 2/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044261 0.88 CTPS1 (0.48) CTPS1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL22490778 0.87 CTPS1 (0.48) CTPS1L3MBTL1CTPS2
SCHEMBL22490790 0.83 CTPS1 (0.48) CTPS1HDAC3HDAC4HDAC1HDAC7
SCHEMBL22490817 0.80 SMN1; SMN2 (0.60) CTPS1L3MBTL1POLBMEN1ALDH1A1
SCHEMBL28305561 0.79 L3MBTL1 (0.57) L3MBTL1HDAC3HDAC4HDAC1HDAC7
SCHEMBL22490819 0.79 CTPS1 (0.45) CTPS1HDAC3HDAC4HDAC1HDAC7
SCHEMBL21076844 0.78 CTPS1 (0.65) CTPS1CTPS2ALDH1A1MAPT
SCHEMBL3351804 0.78 L3MBTL1 (0.60) CTPS1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL21044331 0.77 CTPS1 (0.47) CTPS1CTPS2
SCHEMBL21044398 0.76 CTPS1 (0.48) CTPS1CTPS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717465-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-20250263407-A1 Compounds STEP PHARMA S.A.S. (FR) 2025-08-21 US disclosed
US-12319680-B2 Compounds STEP PHARMA S.A.S. (FR) 2025-06-03 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-11505547-B2 Compounds STEP PHARMA S.A.S. (FR) 2022-11-22 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
EP-3717465-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183229-A1 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885L3MBTL1 3515/4885HDAC3 843/4885
US-12319680-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885L3MBTL1 3515/4885HDAC3 843/4885
US-20250263407-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CTPS1 2586/4885L3MBTL1 3518/4885HDAC3 675/4885
US-11505547-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885L3MBTL1 3515/4885HDAC3 843/4885
US-20210380575-A1 COMPOUNDS UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885L3MBTL1 3515/4885HDAC3 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.